NCT02164500View on ClinicalTrials.gov

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 17, 2019

Study Completion Date

May 17, 2019

Conditions
Recurrent Classical Hodgkin Lymphoma
Interventions
DRUG

Ruxolitinib

Trial Locations (1)

50924

1st Dept. of Medicine, Cologne University Hospital, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT02164500 - JAK-inhibition in Recurrent Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter